Eden Research Plc Reports H1 2025 Results with Strategic Shift and New Product Approvals

Eden Research H1 2025 results: softer first half, strategic shift to a March year-end

Eden Research’s interim numbers show a weather-hit first half and a practical change to the reporting calendar. Management is leaning into seasonality, pushing the year-end to 31 March to better reflect where sales actually land. Guidance of £5.0m revenue is maintained, but now targeted over the 15-month period to 31 March 2026.

Here are the key takeaways and why they matter for shareholders.

Key numbers at a glance

What drove the dip and why it matters

H1 2025 was unusually hot and dry across southern Europe, Eden’s biggest market. That reduces incidence of certain diseases, including Botrytis cinerea, which Mevalone targets. The Company also notes that several customer payments slipped into H2, accentuating the first-half lull.

Worth noting, gross profit held broadly flat at £594,782 despite the lower revenue. By my maths, that implies a stronger gross margin versus last year, likely reflecting mix, pricing, or logistics. Helpful, but not enough to offset higher staff costs as Eden builds the team, which pushed the operating loss to £1.7m.

Cash position and funding stance

Cash was £1.8m at 30 June 2025, with a current balance of £1.9m. Management says it does not currently expect to raise additional funds for existing working capital for the foreseeable future. That is underpinned by expected H2 weighting, typical post-season sales of Mevalone and Cedroz, and anticipated Ecovelex sales in Italy under another emergency use authorisation.

The caveat: additional funding could be pursued to accelerate commercialisation if the right opportunity arises. Eden has also moderated regulatory spend on a pro-rata basis versus FY2024 as the heavy renewal work on three active ingredients tapers.

Strategic shift: moving the year-end to 31 March

This is a sensible change for an agricultural supplier. In the Northern Hemisphere, distributors stock up in Q4 and Q1. A December cut-off can distort reported revenue and inventory precisely when logistics get messy due to factory shutdowns, shipping delays, and partner holidays.

What it means for investors:

• Some December revenue will flow into Q1 2026, so FY2025 performance will be assessed over a 15-month period.
• The Board still expects to meet its £5.0m revenue expectations over those 15 months, subject to Ecovelex emergency use approval in Italy and typical post-season sales.
• From here, interims will cover six months to 30 September and full-year will be the 12 months to 31 March.

Commercial momentum: approvals, partnerships and grants

Mevalone approval in California expands the US opportunity

California cleared Mevalone for powdery mildew on grapes. There are temporary restrictions in the state around personal protective equipment and daily treated acreage that management expects to remove after further dialogue. Removal would materially improve product appeal and market penetration. Eden is working with its US distribution partner to ramp efficiently.

Kenya distribution with Andermatt

Andermatt Kenya is now the exclusive partner for Mevalone in a market that exports high-value crops and cut flowers. First orders are being processed and expected to deliver before year-end, subject to import clearance. Eden plans to expand the label to widen the addressable market.

Diversifying with bee health and non-dilutive funding

A supply agreement with Veto-pharma will see Eden provide thymol for bee care products in the US. Separately, a Knowledge Transfer Partnership with Royal Holloway is accelerating Ecovelex across more cereals and vegetable seeds. Innovate UK funds 67% of this programme, reducing Eden’s cost to 33% while providing specialist expertise and a subsidised associate.

Product-by-product outlook

Mevalone

Sales are expected to grow in the 15 months to 31 March 2026, with traction in Spain and Greece and first sales in Germany. A notable industry shift is coming as Syngenta’s Switch is expected to be withdrawn in the EU, potentially opening share for Mevalone and its evolution, Novellus+.

Cedroz

Cedroz is benefiting from competitor withdrawals in the EU and broader adoption as a bionematicide. Eden expects the growth trend to continue as labels expand and the commercial strategy is refined in key countries.

Ecovelex

Ecovelex has had temporary approvals in Italy and remains supported by farmers as a bird-repellent seed treatment for maize. Another temporary approval in 2025 is not yet certain and could carry hectarage limits, which would affect sales to partner Corteva. Full EU authorisation is anticipated within the next year, but timings in EU crop protection are inherently hard to predict.

Insecticides and pipeline

Eden’s first insecticide has seen over three hundred field trials across potential partners over three years, with robust results. Commercial discussions on distribution are in advanced stages and aimed at maximising value and margins. A second insecticidal product targeting lepidoptera is showing promise, while a second-generation fungicide for late blight in potatoes is progressing with third-party trials and a large potential market as conventional chemistries exit.

Guidance and potential upside catalysts

Base case: at least £5.0m revenue over the 15 months to 31 March 2026, dependent on another Italian emergency use authorisation for Ecovelex and normal post-season sales of Mevalone and Cedroz.

Upside swing factors flagged by the Company:

• Full EU authorisation for Ecovelex well before year-end, enabling broader, longer-term use.
• French approval of Mevalone for downy mildew (marketed as Esseva).
• Signing of an exclusive commercial agreement for Eden’s insecticide.

Risks to keep in view

• Weather sensitivity and seasonality can skew half-year comparisons and near-term demand.
• Regulatory timing is uncertain. Italian emergency use may not be granted or could be restricted by hectarage caps.
• US momentum depends on removal of California restrictions on Mevalone use.
• Cash is tighter year on year; management does not expect a working-capital raise, but acceleration funding remains a possibility.

Josh’s take

Operationally, this reads like a reset rather than a rethink. The hotter, drier H1 hurt Mevalone demand, but Eden maintained gross profit and kept investing £0.7m into its intangible pipeline. The year-end move is pragmatic and should produce cleaner revenue recognition around the critical Q4-Q1 window.

The investment case hinges on three levers: regulatory tailwinds as conventional chemistries exit, near-term catalysts for Ecovelex and Mevalone, and the monetisation of the insecticide franchise. If Italy comes through again for Ecovelex and California relaxes restrictions, the 15‑month revenue target looks achievable. Execution on the insecticide deal would be a strong signal.

Bottom line: a weather-weakened half, sensible housekeeping on reporting, and a pipeline that is getting more interesting. It is not without risk, but the direction of travel remains positive if the regulatory dominoes fall as hoped.